Sequenom to Continue to Lead the US NIPT Market by 2018
The market for non-invasive prenatal diagnostics tests in the US is currently dominated by Sequenom as it got the first mover advantage in the industry. With around 50% market share in terms of volume, Sequenom boasts of having effective marketing strategies that seek to encourage US physicians to recommend its MaterniT21 plus test. In terms of value, Sequenom will remain the market leader in 2018 as well accounting for over 45% of the total market share.
View full press release